218 related articles for article (PubMed ID: 25034116)
1. Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma.
Mantel I; Schalenbourg A; Bergin C; Petrovic A; Weber DC; Zografos L
Am J Ophthalmol; 2014 Oct; 158(4):693-701.e2. PubMed ID: 25034116
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.
Mahdjoubi A; Najean M; Lemaitre S; Dureau S; Dendale R; Levy C; Rouic LL; Desjardins L; Cassoux N
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):411-420. PubMed ID: 29116399
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.
Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E
Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029
[TBL] [Abstract][Full Text] [Related]
5. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
6. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection.
Ishibashi S; Tawara A; Sohma R; Kubota T; Toh N
Arch Ophthalmol; 2010 Dec; 128(12):1539-45. PubMed ID: 21149776
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma.
Shah SU; Shields CL; Bianciotto CG; Iturralde J; Al-Dahmash SA; Say EAT; Badal J; Mashayekhi A; Shields JA
Ophthalmology; 2014 Jan; 121(1):269-275. PubMed ID: 24139123
[TBL] [Abstract][Full Text] [Related]
8. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C.
Alkawas AA; Shahien EA; Hussein AM
J Glaucoma; 2010 Dec; 19(9):622-6. PubMed ID: 20179624
[TBL] [Abstract][Full Text] [Related]
9. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Batioğlu F; Astam N; Ozmert E
Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion.
Fong KC; Barry C; McAllister IL
Clin Exp Ophthalmol; 2009 Jul; 37(5):485-9. PubMed ID: 19624345
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma.
Yeung SN; Paton KE; Waite C; Maberley DA
Can J Ophthalmol; 2010 Jun; 45(3):269-73. PubMed ID: 20379286
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF intravitreal bevacizumab for radiation-associated neovascular glaucoma.
Nagendran ST; Finger PT
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):201-7. PubMed ID: 25707045
[TBL] [Abstract][Full Text] [Related]
13. Intracameral bevacizumab for iris rubeosis.
Grisanti S; Biester S; Peters S; Tatar O; Ziemssen F; Bartz-Schmidt KU;
Am J Ophthalmol; 2006 Jul; 142(1):158-60. PubMed ID: 16815268
[TBL] [Abstract][Full Text] [Related]
14. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.
Ehlers JP; Spirn MJ; Lam A; Sivalingam A; Samuel MA; Tasman W
Retina; 2008 May; 28(5):696-702. PubMed ID: 18463512
[TBL] [Abstract][Full Text] [Related]
15. Management of neovascular glaucoma with transscleral cyclophotocoagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser and intravitreal bevacizumab.
Fong AW; Lee GA; O'Rourke P; Thomas R
Clin Exp Ophthalmol; 2011; 39(4):318-23. PubMed ID: 20973900
[TBL] [Abstract][Full Text] [Related]
16. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab.
Wittström E; Holmberg H; Hvarfner C; Andréasson S
Eur J Ophthalmol; 2012; 22(4):563-74. PubMed ID: 22139613
[TBL] [Abstract][Full Text] [Related]
17. [Results of trabeculectomy with anti-VGEF therapy in the treatment of neovascular glaucoma secondary to retinal vein occlusion (report of 21 cases followed at Bukavu Eye Clinic from January 1 to December 31th, 2015)].
Kabesha TB; Kabesha D; Maloba V; Mwamba C; Chenge B; Mukalay A
J Fr Ophtalmol; 2017 Jan; 40(1):17-21. PubMed ID: 27884546
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
Ramasubramanian A; Shields CL
Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.
Lüke J; Nassar K; Lüke M; Grisanti S
Graefes Arch Clin Exp Ophthalmol; 2013 Oct; 251(10):2403-13. PubMed ID: 23893090
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up.
Arcieri ES; Paula JS; Jorge R; Barella KA; Arcieri RS; Secches DJ; Costa VP
Acta Ophthalmol; 2015 Feb; 93(1):e1-6. PubMed ID: 24989855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
